ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Hyperuricemia

In brief

The purpose of this study is to evaluate the safety of ALLN-346 in healthy volunteers, in this first in human, single ascending dose study. ALLN-346 is an enzyme that degrades urate in the gastrointestinal tract.

Key facts

Study ID
NCT04236219
Run by
Allena Pharmaceuticals
People needed
24
Starts
2020-09-02
Expected to finish
2020-11-06
Last updated by the study team
2021-07-23

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.